Extending the labeled shelf life or expiration dating period of a biologic autoinjector is a consequential post-approval change with direct implications for supply chain planning, product distribution timelines, and regulatory compliance. Regulatory affairs and CMC teams must understand the correct submission pathway before initiating stability programs intended to support extended dating, as selecting the wrong supplement type can delay approval or trigger compliance risk.
The analysis below examines CDER's classification of shelf-life extension changes for autoinjector and prefilled-pen presentations of biological products, drawing on BLA supplement records, action letters, and review memoranda from the past five years to identify the submission category CDER consistently requires.
Want Rhizome's help on your own question? Try it for free.
The BLA supplement CDER requires to extend an autoinjector's labeled shelf life
Bottom line
For an autoinjector (a drug/biologic-device combination presentation), CDER treats a change to the labeled shelf life or expiration dating period as a major manufacturing/CMC change and requires a Prior Approval Supplement (PAS) to a BLA. The applicant must obtain FDA approval before distributing product under the new dating period, and the supplement must be supported by real-time and accelerated stability data plus autoinjector functional/device-aging data. This is documented directly in recent approval letters that describe these submissions as a "Prior Approval supplemental biologics application" or a "Prior Approval Supplement (PAS)." 17383199
In Drugs@FDA metadata, the same PAS can surface under different submission class codes depending on what else it carries, most often Manufacturing (CMC), but sometimes Efficacy or Labeling when the shelf-life/storage change travels with an instructions-for-use or presentation change. The regulatory vehicle in every case is a prior-approval supplement, not a CBE-30, CBE-0, or annual report. 8489186
What the recent record shows (2021 to 2026)
SKYRIZI (risankizumab-rzaa), BLA 761105, supplements 9 and 10 (approved April 2021)
The clearest recent example. The action letter states: "This Prior Approval supplemental biologics application provides for a change to a new 150 mg/mL formulation and product presentation ... The purpose of the supplemental BLA (sBLA) S-010 is to propose a new autoinjector product presentation using the 150 mg/mL formulation." 173177 The CMC review labels them "These prior approval supplements." 69 The submission included a "shelf-life change for DS and shelf-life change for PFS," 75 and the 24-month dating period at 2 to 8°C for the autoinjector presentation was supported by real-time and accelerated stability, including a simulated-aging assessment where "storage at 38°C for 92 days (3 months) simulates 24 months storage at recommended storage conditions" and results that "support the claim for 24 months shelf-life at recommended conditions." 162164
REPATHA (evolocumab), BLA 125522, supplement 45 (approved August 2025)
Explicitly identified in two ways: "This Prior Approval sBLA provides for changes to the SureClick autoinjector Instructions for Use, Reference Guide, and carton labeling," 226 and "The Applicant, Amgen Inc., submitted a Prior Approval Supplement (PAS)." 83 This supplement is useful because it confirms the PAS route is the standard vehicle for SureClick autoinjector combination-product changes even when the change is labeling/IFU rather than a dating extension; the 30-day room-temperature allowance was unchanged. 83237
SIMPONI (golimumab) SmartJect autoinjector, BLA 125289, supplements 156 and 157 (approved October 2025)
The s156 approval letter describes the submission as a "Prior Approval supplemental biologics application." 199 Across s156/s157 the SmartJect autoinjector labeling moved from a fixed 30-day room-temperature use period to an expiration-dated device ("Do not use SIMPONI SmartJect if the expiration date has passed"). 206186 In Drugs@FDA metadata, s157 carries the Efficacy submission class code because the dating/storage change traveled with the FDA-approved Instructions for Use. 186 Older precedent on the same product reinforces the CMC basis: the 2013 SmartJect supplement (s103) extended autoinjector shelf life using real-time (2 to 8°C) and accelerated (25°C/60% RH) functional stability plus device design-verification aging data (delivery time, cap-removal/actuation force, appearance). 134
Biosimilar autoinjectors: YUFLYMA and PYZCHIVA
Two biosimilar examples show the PAS surfacing under the Manufacturing (CMC) class code when the supplement adds/qualifies an autoinjector presentation and its dating:
- YUFLYMA (adalimumab-aaty), BLA 761219, supplement 1, classified Manufacturing (CMC); labeling permits storing the Auto-injector at room temperature up to 31 days. 84
- PYZCHIVA (ustekinumab-ttwe), BLA 761373, supplement 1, classified Manufacturing (CMC); the supplement added autoinjector presentations whose shelf life is supported by stability data. 899097
Why it is a Prior Approval Supplement, not a lighter category
An extension of the labeled expiration dating period is a change with substantial potential to affect product quality, so it must be approved by FDA before the longer-dated product is distributed. The recent CDER record confirms this: every autoinjector shelf-life/dating or presentation change identified above was handled as a prior-approval supplement, and none was processed as a Changes-Being-Effected (CBE-30/CBE-0) supplement or reported only in an annual report. 17383199 For autoinjectors specifically, the stability package CDER expects is two-part: drug-product/prefilled-syringe stability (which sets the ceiling on dating) plus autoinjector functional stability and device design-verification/aging data demonstrating the delivery mechanism still performs at end of the proposed dating period. 7516234
An important carve-out to keep in mind: where a shelf-life extension is executed exactly per a stability protocol already approved in the BLA, FDA's post-approval change framework can allow reporting in an annual report rather than a PAS. None of the recent autoinjector examples in the record were handled that way; all were prior-approval supplements. 17383199
Caveats
The Drugs@FDA "submission class code" is a metadata tag, not the regulatory reporting category, so the same PAS appears as Manufacturing (CMC), Efficacy, or Labeling depending on the full content of the submission; readers should not equate a "Labeling" or "Efficacy" tag with a lighter reporting category. 18684 Several recent action letters and reviews confirm the PAS classification and the presentation/dating change but do not always publish the exact numeric before/after shelf-life value or the full stability tables, so precise dating numbers for a given supplement may require the sponsor's CMC module. 186199